1
Clinical Trials associated with Donor Alloantigen Reactive Tregs(Rho Federal Systems Division)Safety of Donor Alloantigen Reactive Tregs to Facilitate Minimization and/or Discontinuation of Immunosuppression in Adult Liver Transplant Recipients (CTOTC-12)
This research study is for liver transplant recipients and their respective living donors.
The purpose of this study is:
To see if it is safe for liver recipients to receive one dose of donor reactive T regulatory cells (Tregs)
To see if the Tregs allows a liver recipient to take less, or completely stop medications normally taken after receiving an organ transplant.
100 Clinical Results associated with Donor Alloantigen Reactive Tregs(Rho Federal Systems Division)
100 Translational Medicine associated with Donor Alloantigen Reactive Tregs(Rho Federal Systems Division)
100 Patents (Medical) associated with Donor Alloantigen Reactive Tregs(Rho Federal Systems Division)
100 Deals associated with Donor Alloantigen Reactive Tregs(Rho Federal Systems Division)